Hiv vaccine
AssigneeGlaxosmithkline Biologicals SA
InventorsPatricia BOURGUIGNON, Marguerite Christine Koutsoukos, Clarisse Lorin, Lisa McNally, Gerald Hermann Voss
Life of this patent
Estimating the term…
Abstract
The present invention relates to immunogenic compositions comprising HIV-1 antigens and uses thereof in the prevention and/or treatment of HIV-1. In particular, the invention relates to the use of HIV-1 antigens from one clade in the prevention and/or treatment of disease associated with HIV-1 infection from a heterologous HIV-1 clade.
Claims19
A method of inducing an immune response against HIV-1 in a subject comprising administering to the subject an immunogenic composition comprising:
- a. one or more polypeptides comprising HIV-1 antigens Nef, Pol and Gag or immunogenic fragments thereof;
- wherein Nef, Pol and Gag are from an HIV-1 strain of clade A, B, C, D, E, F, G, H, J, K, or a circulating recombinant form of HIV-1 (CRF);
- and
- b. an adjuvant that is a preferential inducer of a Th1 immune response,
- wherein the induced immune response is against an HIV-1 strain from one or more clades different from the one or more HIV-1 clades in the immunogenic composition.
A method of treating or preventing HIV-1 infection in a subject comprising administering to the subject an immunogenic composition comprising:
- a. one or more polypeptides comprising HIV-1 antigens Nef, Pol and Gag or immunogenic fragments thereof;
- wherein Nef, Pol and Gag are from an HIV-1 strain of clade A, B, C, D, E, F, G, H, J, K, or a circulating recombinant form of HIV-1 (CRF);
- and
- b. an adjuvant that is a preferential inducer of a Th1 immune response, wherein the HIV-1 infection being treated or prevented is from one or more HIV-1 clades different from the one or more HIV-1 clades in the immunogenic composition.
Dependencies are inferred from the claim text.